The final opinions are being given in a court challenge of the Canadian Fed government’s measure to prohibit home cultivation of medical marijuana by doctor-approved patients. If home-grow supporters succeed, the verdict could come as a big blow to the recently implemented MMPR that intended to force all users to purchase medical marijuana from approved commercial producers. The move can have a negative impact on Lexaria Corp (OTCMKTS:LXRP) license approval.
The good news
The verdict can affect Lexaria’s sizable joint deal with Enertopia Corp. to cultivate 10,000 KG of dried medical marihuana annually. It will be no exception to the rule. However, the good thing is that the Lexaria’s management team has not been waiting for an approval. It has bought cannabinoid-related patents with an objective of introducing new products into the United States.
Focus on bioavailability
There are several recreational and medical cannabis users who won’t be surprised to know that smoking is an entirely different experience than CBD edibles. They may not know the reason behind the prevailing difference. In a 2005 trial, the researchers discovered that smoking cannabis was a reason of 30% bioavailability of THC. When it came to oral consumption, it resulted in 4%to 12% bioavailability with significant variable absorption.
The prevailing dynamics becomes a matter of concern when users try to consumer CBD which don’t have any psychoactive influence to measure absorption. In these cases, cannabis users may be disappointed to know that many CBD supplements just pass through the body. They are not being fully absorbed and used in beneficial ways, particularly provided the high price of CBD supplements in the market.
In last trading session, the stock price of Lexaria surged more than 17% to close the trading session at $0.200. The gains came at a share volume of 956,363 compared to average share volume of 199,217.